Why Theravance Biopharma Stock Dived 16% Today
Shares of Theravance Bipharma (NASDAQ: TBPH) really took it on the chin Wednesday. Investors sold off the stock following another clinical-trial flop by the company, and its subsequent announcement of severe belt-tightening.
This morning, Theravance divulged the top-line results from its phase 3 study of Ampreloxetine, a drug aimed at treating symptomatic neurogenic orthostatic hypotension (nOH, essentially a disorder in which the body does not effectively regulate blood pressure).
Image source: Getty Images.
Source Fool.com
